Skip to main
MDWD
MDWD logo

MediWound (MDWD) Stock Forecast & Price Target

MediWound (MDWD) Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 62%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediWound Ltd's product pipeline, particularly with EscharEx, demonstrates significant revenue potential, projected to grow from $6.2 million in 2027 to $97.4 million by 2030, indicating strong market demand for its innovations in wound care. The company's FDA-approved NexoBrid continues to drive robust revenue, supported by partnerships in the U.S. market and growing institutional adoption, as evidenced by the increasing number of burn centers placing orders. Furthermore, the expected ramp-up of its GMP-compliant manufacturing facility is anticipated to increase production capacity six-fold, positioning MediWound to meet rising demand and enhance its financial performance.

Bears say

MediWound Ltd has lowered its 12-month price target to $25 per diluted share from $28, reflecting a decreased outlook on its financial performance. In the third quarter of 2024, the company reported total revenues of $4.4 million, significantly below the consensus estimate of $6.0 million, coupled with a larger net loss of $0.98 per share compared to an anticipated loss of $0.45 per share. Furthermore, despite management's estimation of a $2.5 billion addressable market for EscharEx, the company's continual financial losses raise concerns regarding its ability to capitalize on this potential.

MediWound (MDWD) has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 62% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediWound (MDWD) Forecast

Analysts have given MediWound (MDWD) a Strong Buy based on their latest research and market trends.

According to 13 analysts, MediWound (MDWD) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediWound (MDWD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.